PF-06843195

• CAT Number: I045427
• CAS Number: 2067281-51-8
• Molecular Formula: C20H25F3N8O4
• Molecular Weight: 498.46
• Purity: ≥95%
• Synonyms: 2,2-difluoroethyl (3S)-3-[[6-(2-aminopyrimidin-5-yl)-5-fluoro-2-morpholin-4-ylpyrimidin-4-yl]amino]-3-(hydroxymethyl)pyrrolidine-1-carboxylate
• InChI: InChI=1S/C20H25F3N8O4/c21-13(22)9-35-19(33)31-2-1-20(10-31,11-32)29-16-14(23)15(12-7-25-17(24)26-8-12)27-18(28-16)30-3-5-34-6-4-30/h7-8,13,32H,1-6,9-11H2,(H2,24,25,26)(H,27,28,29)/t20-/m0/s1
• InChIKey: RTOREZYNLPQUKM-FQEVSTJZSA-N
• SMILES: C1CN(CC1(CO)NC2=NC(=NC(=C2F)C3=CN=C(N=C3)N)N4CCOCC4)C(=O)OCC(F)F

PF-06843195 (Cat No.: I045427) is a selective, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a key mediator of inflammation and programmed necrosis (necroptosis). By blocking RIPK1 kinase activity, it disrupts necroptotic signaling pathways, thereby reducing cell death and inflammatory cytokine release. PF-06843195 is used in research to study the role of RIPK1 in inflammatory, autoimmune, and neurodegenerative diseases, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Its selectivity makes it a valuable tool for exploring targeted therapies aimed at modulating cell death mechanisms.

Reference

[1]. Hengmiao Cheng, et al. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). J Med Chem. 2021 Jan 14;64(1):644-661.
[Content Brief]